Skip to main content

Whole-Genomic Sequencing Increases Molecular Diagnostic Yield

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, July 14, 2023 -- Genomic sequencing has a higher molecular diagnostic yield than targeted neonatal gene sequencing for infants suspected of having a genetic disorder, according to a study published in the July 11 issue of the Journal of the American Medical Association.

Jill L. Maron, M.D., M.P.H., from the Women and Infants Hospital of Rhode Island in Providence, and colleagues compared outcomes of genomic sequencing to those of a targeted neonatal gene-sequencing test among 400 hospitalized infants younger than 1 year of age (and their parents) suspected of having a genetic disorder.

Overall, 51 percent of the participants had a molecular diagnostic variant (297 variants were identified, including 134 novel variants). The researchers found that the molecular diagnostic yield of genomic sequencing was 49 percent compared with 27 percent with the targeted gene-sequencing test. Nineteen variants found by the targeted neonatal gene-sequencing test were not reported in genomic sequencing; 164 variants identified by genomic sequencing as diagnostic were not reported by the targeted gene-sequencing test. The median time to return of results was 6.1 and 4.2 days for genomic sequencing and targeted genomic sequencing, respectively; for urgent cases, the time was 3.3 and 4.0 days, respectively. Overall, 19 percent of participants had changes in clinical care, and 76 percent of clinicians viewed genomic testing as useful or very useful for clinical decision-making.

"Genome sequencing can be costly, but in this targeted, at-risk population, it proves to be highly informative," Maron said in a statement. "We are supportive of ongoing efforts to see these tests covered by insurance."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted July 2023

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.